These anti-inflammatory effects of AAT — augmented by an increase in sialylation of AAT [110] — could mitigate the injurious hyperinflammatory response typically seen seven to 10 days after the symptom onset of severe COVID-19. This evidence concerns the gene SERPINA1 and COVID-19.